Drug Maker In Ireland May Revise Asset Sale
Elan Corp, troubled Irish drug maker, says it will seek new buyers for two drugs it agreed in Jan to sell to King Pharmaceuticals for $850 million if litigation significantly delays deal; Elan reports first-quarter loss of $130.2 million, down from $50 million profit in 2002 period; chief executive G Kelly Martin comments on plans to shed assets, phone interview (M)